HMPL 523

Drug Profile

HMPL 523

Alternative Names: HMPL-523; HMPL-523 acetate

Latest Information Update: 23 Jan 2017

Price : $50

At a glance

  • Originator Hutchison MediPharma
  • Class Anti-inflammatories; Antirheumatics
  • Mechanism of Action Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I B cell lymphoma; Haematological malignancies; Lupus vulgaris; Multiple sclerosis; Rheumatoid arthritis
  • Preclinical Chronic lymphocytic leukaemia; Inflammation

Most Recent Events

  • 27 Dec 2016 Phase-I clinical trials in B-cell lymphoma (Second-line therapy or greater) in China (PO) (NCT02857998)
  • 27 Dec 2016 Phase-I clinical trials in Haematological malignancies (Second-line therapy or greater) in China (PO) (NCT02857998)
  • 15 Nov 2016 Pharmacokinetics, pharmacodynamic and adverse event data from a phase I trial in Healthy volunteers presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top